Neoadjuvant therapy gains FDA approval in non-small cell lung cancer

• Type of Material: Article
• Authors: Ticiana Leal, Emory University; Suresh Ramalingam, Emory University
• Language: English
• Date: 2022-07-19
• Publisher: Emory University Libraries
• Publication Version: Final Published Version
• Copyright Statement: © 2022 The Author(s)
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1016/j.xcrm.2022.100691
• Title of Journal or Parent Work: Cell Reports Medicine
• Volume: 3
• Issue: 7
• Start Page: 100691
• End Page: 100691
• Keywords: Antineoplastic Agents, Immunological; Progression-Free Survival; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Antineoplastic Combined Chemotherapy Protocols; Nivolumab; Humans; Neoadjuvant Therapy
• Research Categories: Health Sciences, Medicine and Surgery

Abstract

Forde et al.1 reported on a randomized clinical trial (CheckMate 816) and showed that neoadjuvant therapy with nivolumab plus chemotherapy led to improved event-free survival and pathological complete response rate in patients with resectable non-small cell lung cancer (NSCLC).